Journal Title
Title of Journal: Adv Ther
|
Abbravation: Advances in Therapy
|
Publisher
Springer Healthcare
|
|
|
|
|
|
Authors: William Dunlop Louise Heron Georgia Fox Maire Greaney
Publish Date: 2013/11/06
Volume: 30, Issue: 10, Pages: 933-944
Abstract
The economic burden of asthma on the UK National Health Service NHS is the largest among allergic diseases Current asthma guidelines recommend adding a long acting β2agonist LABA to a lowdose inhaled corticosteroid ICS in patients who are on ICS monotherapy and have uncontrolled asthma The fixeddose combination of fluticasone propionate and salmeterol xinafoate FP/SAL available in a pressurized metereddose inhaler pMDI device is the most commonly prescribed ICS/LABA combination An additional fixeddose combination of fluticasone propionate and formoterol fumarate FP/FORM in pMDI is now available In a 12week noninferiority study FP/FORM demonstrated comparable efficacy to FP/SAL The present analysis estimates the annual budget impact for the UK NHS using FP/FORM as an alternative to FP/SALCurrent pMDI prescribing data were from a realworld UK patient database Cegedim Strategic Data Annual costs to the NHS for drug acquisition administration and monitoring were estimated for FP/FORM and FP/SAL and used to assess the potential budget impact for the NHS for the use of FP/FORM instead of FP/SAL Varying rates of uptake adherence adverse eventrelated costs and resource use associated with switching treatment were assessed in scenario analysesAssuming similar levels of ICS use with both regimens annual drug acquisition costs per person were lower with FP/FORM £412 than with FP/SAL £509 The difference in acquisition costs and otherwise comparable input costs between the treatments results in potential annual savings of £15110279 to the NHS assuming uptake of FP/FORM over FP/SAL in 50 of existing patients The introduction of FP/FORM results in cost savings for the NHS in all of the assessed scenario analysesSponsorship and article processing charges for this study were funded by Mundipharma International Ltd United Kingdom Adelphi Values Ltd received funding from Mundipharma International Ltd to support this research Mr Dunlop is the guarantor for this article and takes responsibility for the integrity of the work as a wholeWilliam Dunlop is an employee of Mundipharma International Ltd United Kingdom Louise Heron is an employee of Adelphi Values Ltd UK Georgia Fox is an employee of Adelphi Values Ltd UK Maire Greaney is an employee of Adelphi Values Ltd UK The authors do not report any conflict of interest with regards to the contents of this study other than those stated
Keywords:
.
|
Other Papers In This Journal:
|